Physician's choice according to patient's needs.: Routine care as per site standard.
Study summary
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced or metastatic ovarian cancer (OC) or advanced or metastatic endometrial cancer (EC) in Germany.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Confirmed high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer):
* patients with FIGO stage IIb-IV OC who are starting systemic treatment or
* patients with recurrent/relapsed disease, who received any previous systemic anti-tumor treatment and who are now starting systemic treatment for recurrent/relapsed disease.
* Locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy.
* Signed and dated informed consent (IC):
* Patients participating in PRO module: IC before first therapy cycle
* Patients not participating in PRO module: IC no later than six weeks after start of first therapy cycle
Exclusion Criteria:
* newly diagnosed early-stage OC (FIGO stage I-IIa)
* Low grade mOC OR
* Early-stage EC (FIGO stage I-II)
Primary outcome measure(s)
Course of treatment (treatment reality). — 3 years per patient Documentation of anamnestic data and therapy sequences.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.